Median Reduction of Seizure Frequency of 35.7% Over Placebo was Achieved in the 60 mg Treatment Arm Neurological Effects and Other Adverse Effects (AEs) Similar to Placebo NEW YORK, Jan. 30, 2023 /PRNewswire/ -- Equilibre Biopharmaceuticals Corp., a clinical stage biopharmaceutical company focused on neurological diseases, today reported positive topline results from the Phase 2 clinical...